Radar Therapeutics
Developer of precision-expressed mRNA therapeutics that use transcriptome-based sensing to restrict therapeutic activity to desired cell types. The company combines analysis of single-cell transcriptomic datasets, engineered RNA sensors and RNA-editing–based control mechanisms to create mRNA constructs that "read" cell state and conditionally "write" therapeutic functions in vivo. Activities include platform development, preclinical validation, peer-reviewed publications, and early-stage commercialization efforts.
Industries
Nr. of Employees
small (1-50)
Radar Therapeutics
Products
Platform for precision-controlled mRNA therapeutics
A platform that combines transcriptome-driven target identification, engineered RNA sensors, and RNA-editing–based control to produce mRNAs that express therapeutic functions only in intended cell types and contexts.
RADAR platform
A platform enabling precision therapeutics through targeted, timely, and controlled reading of the mRNA message in just the right cells, avoiding toxic side-effects in non-target cells.
Platform for precision-controlled mRNA therapeutics
A platform that combines transcriptome-driven target identification, engineered RNA sensors, and RNA-editing–based control to produce mRNAs that express therapeutic functions only in intended cell types and contexts.
RADAR platform
A platform enabling precision therapeutics through targeted, timely, and controlled reading of the mRNA message in just the right cells, avoiding toxic side-effects in non-target cells.
Expertise Areas
- Precision mRNA therapeutics
- RNA sensor engineering
- Single-cell transcriptomic analysis
- Synthetic biology and genetic circuits
Key Technologies
- mRNA therapeutic design
- Single-cell RNA sequencing / transcriptomics
- ADAR-mediated RNA editing
- Autocatalytic base editing for RNA
News & Updates
Announcement of company launch focused on targeted mRNA treatments using transcriptome-harnessing RNA sensors.
Raised $13.4M in seed funding to develop programmable medicines using molecular RNA sensors.
Publication describing modular, programmable RNA sensing using ADAR editing in living cells.
Publication describing autocatalytic base editing strategies for RNA-responsive control of translation.
Recipient of Wacker Biotech Discovery Award.
Selected for a Bakar Labs program in collaboration with AbbVie.
Announcement of company launch focused on targeted mRNA treatments using transcriptome-harnessing RNA sensors.
Raised $13.4M in seed funding to develop programmable medicines using molecular RNA sensors.
Publication describing modular, programmable RNA sensing using ADAR editing in living cells.
Publication describing autocatalytic base editing strategies for RNA-responsive control of translation.
Recipient of Wacker Biotech Discovery Award.
Selected for a Bakar Labs program in collaboration with AbbVie.